CRNX News and Press, Crinetics Pharmaceuticals Inc. From 09/12/23

SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing ...

2023-09-11 16:12:13 ET More on Crinetics Pharmaceuticals Seeking Alpha’s Quant Rating on Crinetics Pharmaceuticals Historical earnings data for Crinetics Pharmaceuticals Financial information for Crinetics Pharmaceuticals Crinetics Pharmaceuticals: Cre...

2023-09-11 12:58:57 ET Gainers: Super League Gaming ( SLE ) +182% . Crinetics Pharmaceuticals ( CRNX ) +66% . Aurora Cannabis ( ACB ) +55% . Canopy Growth Corporation ( CGC ) +46% . Avantax ( AVTA ) +28% . Clever Leaves Holdi...

2023-09-11 12:57:53 ET Shares of Crinetics Pharmaceuticals (NASDAQ: CRNX) were up more than 67% as of 12:30 p.m. ET on Monday after the company posted positive phase 3 trial results for one of its therapies. The healthcare stock is up more than 28% for the year. Crinetics fo...

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is one of today's top gainers. The company's shares are currently up 67.89% on the day to $26.81. Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic...

2023-09-11 06:53:28 ET More on Crinetics Seeking Alpha’s Quant Rating on Crinetics Pharmaceuticals Historical earnings data for Crinetics Pharmaceuticals Financial information for Crinetics Pharmaceuticals Crinetics Pharmaceuticals: Creating Next-Gener...

2023-09-11 05:18:10 ET More on Crinetics Pharmaceuticals, Tesla, etc. Tesla: When There's A Dividend, Count Me In Tesla: Overvalued Car Company - Likely To Face Further Margin Deterioration Buy Rating For Tesla Ahead Of An Impending Rally Why I Decided To Sho...

83% of Participants on Paltusotine Maintained IGF-1 ≤1.0 xULN vs. 4% on placebo (p<0.0001) Mean IGF-1 Levels Were Maintained on Paltusotine vs. an Increase on Placebo (p<0.0001) After Switching from Injected Depot Standard of Care Mean Acromegaly Symptom Diary S...

2023-08-31 09:42:53 ET More on Crinetics Crinetics Pharmaceuticals: Creating Next-Generation Treatments In Acromegaly Crinetics Pharmaceuticals: Paltusotine Phase 3 Data Presented At ENDO Crinetics says FDA didn’t clear Phase 2 study request for hyperinsulinis...

2023-08-28 18:07:28 ET Summary Crinetics Pharmaceuticals, Inc. is my latest long position. The company has two Phase 3 data releases for Paltusotine in treating acromegaly over the next 7-8 months. Acromegaly is a disorder caused by excess levels of growth hormone, and current...